“We are excited and proud to announce this collaboration with Dr. Algazi and UCSF with support from Merck. The achievement of this milestone marks the first clinical trial to evaluate the combination of an anti-PD-1 antibody with an intratumoral therapy using electroporation,” commented Punit Dhillon, President and CEO of OncoSec."
The collaboration is with UCSF, not Merck. It is pretty simple.